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Abstract 
Aims: Systemic Lupus Erythematosus (SLE) is a connective tissue disease characterized by a wide range of 
pleomorphic pictures, including mucocutaneous, renal, musculoskeletal and neurological symptoms. It involves 
oral tissues, with hyposalivation, tooth decay, gingivitis, angular cheilitis, ulcers and glossitis. 
Temporomandibular disorders represent a heterogeneous group of inflammatory or degenerative diseases of 
the stomatognatic system, with algic and/or dysfunctional clinical features involving temporomandibular joint 
(TMJ) and related masticatory muscles. The aim of this study was to investigate the prevalence of oral 
manifestations and temporomandibular disorders (TMD) in SLE patients (Lp) compared with a control group. 
Methods: Fifty-five patients (9 men and 46 women) with diagnosed Lupus were recruited in the study group. 
A randomly selected group of 55 patients, matched by sex and age, served as control group. The examination 
for TMD symptoms and signs was based on the standardized Research Diagnostic Criteria for 
Temporomandibular Disorders (RDC/TMD) through a questionnaire and clinical examination. 
Results: Lupus patients complained more frequently (95.8%) of oral and TMJ symptoms (dysgeusia, 
stomatodynia, masticatory muscle pain during function, neck and shoulder muscles pain and presence of 
tinnitus) but only xerostomia (χ2=4,1548 p=0,0415), temple headache (χ2=4,4542 p=0,035) and the sensation 
of a stuck jaw (Mid-p-test p=0,043) were significant. About signs, cheilitis (p=0,0284) oral ulcers (χ2=4,0104 
p=0,045) and fissured tongue are significantly more frequent in study group. The salivary flow was significantly 
decreased in the study group respect to the control one (p<0.0001). As regard to the oral kinematics, 
restricted movements (RM) in protrusion and left lateral movement were significantly different between study 
group and controls. In particular, 85,2% of Lp showed limited protrusion versus 56,4% of controls (χ2= 10,91 
p<0,001); 59,3% of Lp had also a limitation during left lateral movement versus 47,3% of controls (T=2,225 
p=0,0282). About bruxism, only the indentations on the lateral edges of the tongue were found in Lp group 
(72,7%), with a significant difference respect to controls (χ2=7,37 p=0,007). 
Conclusions: While masticatory muscles have an overlapping behavior in both groups, the findings collected 
show a more severe TMJ kinematic impairment in Lp than in controls, with protrusion and left lateral 
movements significantly different. In addition, a remarkable reduction of salivary flow has been detected in Lp 
compared to controls. In conclusion, this autoimmune disease seems to play a role in oral manifestations and 
TMJ disorders, causing an increase in orofacial pain and an altered chewing function. 
Key words: Systemic Lupus Erythematosus, oral features, temporomandibular disorders, RDC/TMD  
Introduction 
Lupus Erythematosus (LE) is a connective tissue 
disease and can be classified into two major forms: the 
systemic (SLE) and cutaneous (CLE) one. The former 
is a chronic, multisystem, rheumatic disorder, present 
at any age, with an etiology still unknown. It has a 








cutaneous, renal, musculoskeletal and neurological 
symptoms. 
The latter is further divided into three subtypes: 
acute (ACLE), subacute (SCLE) and chronic (CCLE) 
[1]. The discoid LE (DLE) is the most common variant 
of CCLE, characterized by erythematosus macules 
and plaques, follicular occlusion, desquamation, 
telangiectasia and atrophy. The two categories can 
occur together or separately [2].  
Annual estimated incidence of SLE from 1970s to 
2000s is about 1-10/100.000 and the prevalence is 
about 5.8-13/100.000. Cutaneous forms are 
considered 2-3 times more frequent than systemic one 
[3]. Women between 15 and 40 years are more 
frequently affected than men, with a preponderance 
of 6 up 10:1 [4,5]. Although Juvenile SLE (JSLE) is 
rarer, children usually experience higher disease 
activity and a more aggressive course compared to 
adults [6].  
The mortality rate associated with the condition 
is around 3–5 times higher than that observed in the 
general population and is mostly attributed to the 
chronic inflammatory processes [7].  
Pathogenesis of LE is multifactorial, involving 
genetic and environmental triggers [5]. About genetic 
factors, population studies reveal a relationship 
between the susceptibility to LE and human leukocyte 
antigens (HLA) class II and class III genes 
polymorphism. In patients with the expression of 
HLA DR2 and DR3, SLE autoantibodies are produced: 
(i) extractable nuclear antigens or ENA, such as 
anti-Ro, anti-Sm, anti-La, anti-nRNP; (ii) antinuclear 
antibodies or ANA, such as anti-dsDNA and 
anti-ssDNA. Moreover, patients with complement 
component C1q deficit have the highest risk to 
develop LE, because of a reduced clearance of 
apoptotic bodies. 
Also sex hormones and a defective 
hypothalamus-pituitary-adrenal (HPA) axis influence 
the susceptibility and the progression of the disease. 
In fact, increased estrogenic and reduced androgenic 
hormonal activity has been demonstrated in SLE 
patients (Lp) of both sex. Moreover, HPA axis is 
involved in the stress system, by increasing 
glucocorticoids, which results essential for prevention 
of dysregulated autoimmune answer. Environmental 
factors include infectious agents, diet, toxins/drugs, 
physical/chemical agents, hair dyes and tobacco 
smoke [8]. 
Clinically the disease has a variable course and a 
relapsing-remitting trend [4]. Several organs and 
systems are affected (muscles, skeleton, joints, lungs, 
kidneys, skin, blood vessels, nervous system), so the 
pathology is characterized by different manifesta-
tions. The most frequent and characteristic feature is 
the malar rash (“butterfly” rash), associated with 
arthritis, glomerulonephritis, psychosis and seizure, 
serosity, fever, fatigue, weight loss, anemia [9]. 
Mucocutaneous involvement includes alopecia, 
discoid lesions, photosensitivity and oral lesions [4]. 
These are red macules or plaques, often localized on 
the hard palate, leukoplakic plaques, typical of buccal 
mucosa, lichenoid lesions, and ulcers on lips. 
Hyposalivation predispose patients with SLE to 
an increased risk of developing caries, gingivitis and 
periodontal disease, fungal infections, especially with 
Candida species, exfoliative or angular cheilitis and 
glossitis, with hyperemic and smooth tongue because 
of loss of papillae. A high prevalence of oral 
complaints such as dysphagia, dysgeusia, and 
glossodynia is also present, while trigeminal 
neuralgia is rare [10,11,12,13,14,15,16 17,18].  
Temporomandibular disorders (TMD) is a 
generic term referred to clinical conditions involving 
the jaw muscles and temporomandibular joint (TMJ). 
Such disorders are related to stress, age, gender, 
malocclusion and other systemic factors. It is 
estimated that about one third of adults suffer from 
TMD symptoms (TMDs) [19,20,21].  
TMJ can be affected in patients with SLE as they 
have changes in the condyles, including flattening, 
cortical erosions, osteophytes, sub cortical cysts, 
sclerosis and gradual decrease in joint space due to 
granulation. This involvement can be linked to 
disease activity, leading to a breakdown of the 
cartilage matrix and bone destruction. Myopathies, 
with reduced masticatory muscle strength and 
atrophy, may be part of the disease condition or 
associated with a long term use of corticosteroid 
therapy [22,23,24,25]. 
Nevertheless, the literature lacks studies about 
TMJ and masticatory muscles involvement in patients 
with SLE, so the relationship between this disease and 
the temporomandibular disorders is unclear. Given 
this background, the aim of this study was to 
investigate clinically, through signs and symptoms, 
the prevalence of oral manifestations and 
temporomandibular disorders in Lp on drug therapy 
compared with a control group (CG), thus giving a 
complete survey of facial involvement in course of 
LES. The null hypothesis in this research was that Lp 
presented no differences in clinical characteristics and 
functional disabilities compared to a control group. 
Materials and Methods  
This observational study was conducted from 
January 2016 to February 2019 at the School of 
Dentistry and the Department of Rheumatology, 
University of Bari, Italy, in accordance with the 
provisions of the Declaration of Helsinki. Ethical 




approval and informed consent were obtained from 
each human subject.  
Fifty-five patients (9 men and 46 women) with 
diagnosed Lupus (Lp) were recruited in the study 
group.  
Inclusion criteria were: age>18 years and 
Caucasian ethnic origin. Exclusion criteria were: 
traumatic diseases, head, oral or neck neoplasia, past 
or present chemotherapy and radiotherapy, 
neurological disorders, maxillofacial treatments, past 
or present orthodontic treatment. Patients with other 
rheumatic diseases were excluded from the study. A 
control group (CG) of 55 subjects, matched by sex 
with the study group and with no immune disease 
history, was randomly chosen among those 
presenting at the Dental Clinic. Patients age ranged 
between 18 and 85 years, with a mean age of 44,44 (SD 
= 15,04) years in the Lp group and 46 years (SD = 
13,49) in the CG.  
TMD signs and symptoms were valued 
following the standardized Research Diagnostic 
Criteria for Temporomandibular Disorders 
(RDC/TMD) [19].  
A single experienced practitioner assessed TMD 
and orofacial manifestations through an anamnestic 
questionnaire and a clinical examination. 
Patients history 
Oral symptoms 
Through a questionnaire, patients listed the 
presence/absence of the following disorders: 
(i)Xerostomia: characterized by dry mouth and 
associated to discomfort especially when they eat, 
speak, swallow and wear dentures. Less stringy and 
foamy saliva is produced [12]. 
(ii)Dysgeusia: defined a distorted gustatory 
perception. Patients report that they perceive bitter, 
sour, or metallic flavours [13]. 
(iii)Stomatodynia: a burning sensation in the 
mouth, associated with hurtful sensation or pain, even 
though oral mucosa appears clinically normal [14,15]. 
TMD symptoms 
TMDs: they include muscle pain, neck and upper 
shoulders stiffness, pain at masticatory muscles 
during mandibular functions, arthralgia (tenderness 
or pain in TMJ area), a feeling of locked jaw, 
headaches, especially at the temples [16,19]. 
Dizziness, earache and tinnitus are other less common 
problems that these patients also complained [26,27]. 
Patients described how much the disease was serious 
according their perception by using VAS scale (from 
slight tenderness to unbearable pain) and if they had a 
periodical or continuous symptomatology since the 
disease was diagnosed. 
Myofascial pain (MP): while palpation does not 
elicit sensations of tenderness or pain in healthy 
muscles, ache may be provoked by compression of 
contract or inflamed muscles. The following 
masticatory muscles were palpated bilaterally: 
anterior, medial and posterior temporalis muscles, 
masseter muscle, medial pterygoid muscle, lateral 
pterygoid muscle with its superior and inferior head, 
digastric (anterior and posterior belly) muscle and 
mylohyoid muscles. Palpation was performed 
applying soft but firm pressure to the muscle mainly 
with the palmar surface of the thumb and of the index 
finger. 
Clinical examination 
Lupus oral signs 
Oral ulcers: presence of oval or roundish sores 
inside the mouth.  
Petechiae: red or brown pinpoint lesions not 
blanching on pressure, localized more frequently on 
the hard and soft palate [28]. 
Erythema: reddish and inflamed area on buccal 
mucosa. 
Fissured tongue: anatomical condition of the 
tongue surface, usually asymptomatic. Grooves are 
distributed across the dorsal surface of the tongue and 
can vary in size and depth. 
Cheilitis of lower lip: it is an inflammation state, 
characterized by redness, swelling and ulcers on 
lower lip. 
Hyposalivation: the test was conducted asking the 
patient to spit saliva accumulated in the floor of the 
mouth without stimulation in a graduated tube every 
60 seconds. The collection period lasted 5 minutes 
[29]. 
Other oral characteristics analyzed were the 
integrity of the dental arches or presence of partial or 
total edentulism, the presence/absence of prostheses 
(mobile, fixed or both).  
TMJ signs 
TMJ sounds (TMJs): they were appreciated by 
palpation on each side separately on mandible 
movement. They can be classified in: (i) clicking, (ii) 
crepitation. Clicking is defined as a single, clear joint 
sound of short duration. Crepitation is a sound 
similar to a rough multiple, gravel-like sound [20]. 
Bruxism (BRUX): it is a stereotypical jaw 
movement, characterized by clenching and gnashing 
of the teeth, during sleep or when awake [30]. By time, 
flattening of the dental cusps or dental mobility can 
occur. Bruxism is considered pathological when it 
causes myalgia (due to a prolonged vasoconstriction 
and to accumulation of catabolites in the muscle 
tissue) and joint pain [31]. 




Opening derangement (OD): in a healthy 
condition, the mandible-opening path (observing the 
lower midline) is straight. Alterations of the opening 
trajectory are:  
(i) deviation: any shift of the jaw midline during 
opening that disappears with continued opening (a 
return to midline); 
(ii) deflection: any shift of the midline to one side 
that increases with opening and persists at maximum 
opening [32]. 
Restricted movements (RM) 
They are classified as: 
(i) reduced opening: in a healthy system, the 
mouth opens by between 53 and 58 mm. Taking into 
account overbite [33], a restricted mandibular opening 
is considered to be any distance of <40 mm; 
(ii) reduced right and left lateral excursions, 
measured from upper to lower midline, when the 
distance is <8 mm; 
(iii) a mandibular advancement: it is considered 
reduced when <7mm [34,35]. 
Statistical analysis 
Continuous data were presented as mean and 
Standard Deviation (SD) and the comparisons 
between Lp and controls were assessed by means of 
Student’s T test for unpaired samples. Categorical 
data were expressed as number and percentage and 
Chi-squared (with Mantel-Haenszel or Yates’ 
corrections). Mid-P or Fisher Exact Tests were 
employed to compare two groups. A two-tailed p 
value ≤0.05 was considered as statistically significant. 
Statistical analyses were performed using Prism 
(GraphPad software, version 6.0, San Diego, 
California). 
Results  
Characteristics of Lupus patients (Lp) and 
controls 
The prevalent form of disease was the systemic 
one (SLE), found in the 90,9% of Lp. The age at 
diagnosis varied between 12 and 84 years (mean=32,9 
years, SD = 16,07) with a disease mean duration of 
8,04 years (SD = 8); 43,6% of patients had the 
pathology for less than 5 years.  
The two groups, matched for age and sex, 
resulted similar for sociodemographic aspects, except 
for educational degree (χ2=9,4184 p=0,0242) and 
occupation (χ2=21,6894 p=0.0014). About education, 
high school degree was prominent in both groups, but 
graduates were more than double among controls. As 
regard to occupation, among Lp group housewives 
and jobless prevailed, while among controls public 
employees were prominent (Table 1).  
Clinical characteristics of Lp patients and 
controls are reported in Table 2. The principal drugs 
for Lp patients and controls are reported in Table 3. 
 




Lp Controls Test p Value  
Age, mean±SD 44,44±15,04 46±13,49   
Sex, n (%)     
Male 9 (16,4%) 9 (16,4%)   
Female 46 (83,6%) 46 (83,6%)   
Educational degree, n (%)  χ2=9,4184 0,0242 
Primary 8 (14,5%) 5 (9,1%)   
Secondary 17 (30,9%) 7 (12,7%)   
High 25 (45,5%) 29 (52,7%)   
Academic 5 (9,1%) 14 (25,5%)   
Occupation, n (%)   χ2=21,6894 0,0014 
Housewife 18 (32,7%) 13 (23,6%)   
Retired 5 (9,1%) 5 (9,1%)   
Office Worker 12 (21,8%) 11 (20%)   
Self Employed 3 (5,5%) 4 (7,3%)   
Not Employed 12 (21,8%) 1 (1,8%)   
Public Employee 2 (3,6%) 16 (29,1%)   
Marital status, n (%)   χ2=7,2039 0,0657 
Married 29 (52,7%) 39 (70,9%)   
Widower 1 (1,8%) 2 (3,6%)   
Single 21 (38,2%) 14 (25,5%)   
Divorced 4 (7,3%) 0     
 
Table 2. Comorbidity in Lp and controls. 
Concomitant 
diseases 




Cardiopathy  9 (16,4%) 2 (3,6%) χ2= 4,9045 0,027 
Diabetes mellitus  2 (3,6%) 0 Fisher exact test 0,248 
Esophageal disease  8 (14,5%) 3 (5,5%) χ2= 2,5253 0,112 
Gastritis  2 (3,6%) 0 Fisher exact test 0,248 
Hypertension  12 (21,8%) 6 (10,9%) χ2= 2,3913 0,122 
Hypovitaminosis D 6 (10,9%) 0 Fisher exact test 0,016 
Lung disease 14 (25,5%) 0 χ2= 13,8318 <0,001 
Osteoporosis  10 (18,2%) 1 (1,8%) χ2= 6,4646 0,011 
Presence of 
removable prosthesis 
4 (7,3%) 6 (10,9%) χ2= 0,4400 0,507 
Raynaud syndrome 10 (18,2%) 0 χ2= 8,9100 0,003 
Thyroid disease  12 (21,8%) 5 (9,1%) Mid-p-test 0,036 
Renal disease 26 (47,3%) 0 χ2= 31,4789 <0,001 
Blood disease 24 (43,6%) 0 χ2= 28,1928 <0,001 
Neurological disease  7 (12,7%) 0 Fisher exact test 0,006 
 
Table 3. Lp and controls' drugs. 
Drugs Lp, n (%) Controls n 
(%) 
Test p Value  
Azathioprine 8 (14,5%) 0 Fisher exact test 0,003 
Belimumab 2 (3,6%) 0 Fisher exact test 0,248  
Cyclophosphamide 3 (5,5%) 0 Fisher exact test 0,122  
Cyclosporine 6 (10,9%) 0 Fisher exact test 0,0135 
Corticosteroids 41 (74,5%) 0 Fisher exact test <0,001 
Hydroxychloroquine 31 (56,4%) 0 Fisher exact test <0,001 
Leflunomide 1 (1,8%) 0 Fisher exact test 0,500  
Methotrexate 4 (7,3%) 0 Fisher exact test 0,059  
Mycophenolate Mofetil  15 (27,3%) 0 Fisher exact test <0,001 
Rituximab 2 (3,6%) 0 Fisher exact test 0,248  
 




Table 4. Subjective complaints of oral discomfort in Lp and 
controls. 
Oral symptoms Lp, n (%) Controls, n (%) χ2 p Value  
Xerostomia 17 (30,9%) 8 (14,5%) 4,1548  0,0415 
Dysgeusia 5 (9,1%) 2 (3,6%) 1,3731 0,241 
Stomatodynia 4 (7,3%) 3 (5,5%) 0,1526 0,696 
 
Table 5. TMD symptoms in Lp and controls. 
TMDs Lp, n (%) Controls, n (%) Test  p Value 
Arthralgia 17 (30,9%) 10 (18,2%) χ2= 2,4052 0,121 
Temple headache 29 (52,7%) 18 (32,7%) χ2= 4,4542 0,035 
Sensation of stuck jaw 13 (23,6%) 6 (10,9%) Mid-p-test 0,043 
Masticatory muscle 
pain during function 
14 (25,5%) 8 (14,5%) χ2= 2,0455 0,153 
Neck and shoulder 
muscles pain 
38 (69,1%) 35 (63,6%) χ2= 0,3665 0,545 
tinnitus 16 (29,1%) 10 (18,1%) χ2= 1,8132 0,178 
 
Table 6. Myofascial pain in Lp and controls. 
Muscle Lp, n (%) Controls, 
n (%)  
Test p 
Value  
Anterior temporalis muscles 21 (38,2%) 17 (30,9%) χ2= 0,6433  0,423 
Medial temporalis muscles 16 (29,1%) 12 (21,8%) χ2= 0,7666  0,381 
Posterior temporalis muscles 11 (20,0%) 10 (18,2%) χ2= 0,0589  0,808 
Superficial masseter muscles 29 (52,7%) 25 (45,5%) χ2= 0,5820  0,446 
Deep masseter muscles 29 (52,7%) 26 (47,3%) χ2= 0,3273  0,567 
medial pterygoid muscles 29 (52,7%) 30 (54,5%) χ2= 0,0366  0,848 
lateral pterygoid muscle 30 (54,5%) 37 (67,3%) χ2= 1,8709  0,171 
digastric muscle - anterior belly 10 (18,2%) 11 (20,0%) χ2= 1,0589  0,808 
digastric muscle - posterior belly 13 (23,6%) 18 (14,5%) χ2= 1,4714  0,225 
Mylohyoid muscles 14 (25,5%) 11 (20,0%) χ2= 0,4659  0,495 
 
Table 7. Oral signs for Lp and controls. 




Candidiasis 1 (1,8%) 0 Fisher exact test 0,500 
Cheilitis 5 (9,1%) 0 Fisher exact test 0,0284  
Erythema 3 (5,5%) 0 Fisher exact test 0,122 
Petechiae 3 (5,5%) 0 Fisher exact test 0,122 
Fissured tongue 7 (12,7%) 0 Fisher exact test 0,006  
Oral ulcers 11 (20%) 3 (5,5%) χ2= 4,0104  0,045  
Erythematous and 
hyperkeratotic areas 
2 (3,6%) 0 Fisher exact test 0,248 
Others  4 (7,3%) 12 (21,8%) χ2= 4,6383  0,031  
 
 
Figure 1. Mean values ± SD of Lp and control group. Lp patients show a reduced 
salivary flow. 
Lupus oral symptoms 
Twenty-nine Lp (52,7%) complained of one or 
more oral symptoms compared to 24 of controls 
(43,6%). A statistically significant difference between 
two groups was found only for xerostomia (Table 4). 
TMD symptoms  
The assessment of TMDs showed that 94,5% Lp 
and 90,9% of controls complained one or more 
symptoms. Statistically significant differences weren't 
found between the two whole groups (χ2=0,5392 
p=0,463).  
Arthralgia, temple headache, sensation of a stuck 
jaw, masticatory muscle pain during function, neck 
and shoulder muscles pain and presence of tinnitus 
are more frequent in Lp than in controls, but only 
temple headache (χ2=4,4542 p=0,035) and the 
difficulty in opening mouth (Mid-p-test p=0,043) are 
significant (Table 5). 
Myofascial pain (MP) evoked by palpation was 
detected in 70,9% Lp and 76,4% of controls, revealing 
a similar frequency between Lp and controls 
(χ2=0,4215 p=0,516). Data collected for each muscle 
couple are reported in Table 6. 
Lupus oral signs 
At the clinical examination, 52,7% of Lp have at 
least one oral sign respect to 43,6% of controls, but this 
difference is not statistically significant (χ2=0.91 
p=0,340). However, there are statistically significant 
differences between the two groups for some 
observed signs. Cheilitis, oral ulcers and fissured 
tongue are more frequent in study group. Other signs 
(oral respiration, gingival recessions, herpes labialis, 
BMS) are more frequently observed in controls than 
Lp (χ2=4,6383 p=0,031). Table 7 lists the main findings 
collected from the oral examination. 
Regarding the extent of salivary flow, measured 
in 5 minutes, there was a statistically significant 
reduction in the Lp compared to controls (Student’s T 
Test, p<0,0001). Mean values and SD are: 0.254 ± 0.395 
for Lp and 3.197 ± 0.571 for control group (Figure 1). 
TMJ signs 
As regard to restricted movements (RM), 
protrusion and left lateral movement were 
significantly different between Lp and controls. In 
particular, 85,2% of Lp showed limited protrusion 
versus 56,4% of controls (χ2= 10,91 p<0,001); 59,3% of 
Lp had a limitation during left lateral movement 
versus 47,3% of controls (T=2,225 p=0,0282).  
The prevalence of Opening derangement (OD) 
was higher in Lp (45,20%) than in controls (44,24%), 
although this difference was not statistically 
significant (χ2=0,05 p=0,5347). Measurement data 




related to movements are reported in Table 8. 
Bruxism was more frequent in control group 
than Lupus one (38,2% versus 32,7%). No significant 
difference between the two groups was found for 
wear facets and oral frictional hyperkeratosis 
(morsicatio buccarum). Only the indentations on the 
lateral edges of the tongue were found in Lp group 
(72,7%), with a significant difference respect to 
controls (χ2=7,37 p=0,007). Table 9 lists parafunction 
(bruxism and clenching) signs. 
Finally, joint sounds were more frequent in 
controls (25,5%) than Lp (16,4%) but with no 
statistically significant difference.  
 
Table 8. Restricted Movements (RM). 
Measurements (mm);  
mean±SD 
 Lp Controls T Student p Value  
 
Opening 45,20 ±8,61 44,24 ± 7,65 0,6228 0,5347 
Laterotrusion right 5,85 ± 3,49 6,86 ± 2,5 1,681 0,0957 
Laterotrusion left 6,13 ± 4,02 7,636 ±2,98 2,225 0,0282 
Protrusion 4,09 ± 2,36 6,091 ± 2,75 4,069 < 0,0001 
 
Table 9. Parafunctional signs. 
Parafunctional signs  Lp Controls Test p Value  
Wear facets 32 (58,2%) 25 (45,5%) χ2= 1,7842  0,550  
Oral frictional hyperkeratosis 26 (47,3%) 19 (34,5%) χ2=1,8427 0,175 
Indentations on lateral edges of 
tongue 
40 (72,7%) 25 (45,5%) χ2=7,3709  0,007  
 
Discussion 
The present study analyzed the prevalence of 
symptoms and sign of both mucosal damage and 
temporomandibular dysfunction in Lp compared 
with healthy controls. The present cohort is larger 
respect to the sample size of other studies 
investigating TMD and LE: 55 Lp versus 2 in Liebling 
and Gold [36], 2 in Simoes et al. [37], 22 in Aliko et al. 
[23], 25 in Aceves-Avila et al. [38], 37 in Jonsson et al. 
[39]. Lopez-Labady’s work examined 90 Lp, but only 
oral manifestations were described, while TMD were 
omitted [1]. 
About sociodemographic characteristics, women 
(46 females and 9 males) are more affected than men, 
in accordance with the literature [4,5]. Jobless and 
housewives were most represented in Lp, while 
public employees were most represented among 
controls. About education, graduates were more than 
double among controls. These data could be 
explained with a progressive physical disability in 
patients with SLE. In fact, several comorbidities (Table 
2), such as renal (χ2=31,4789 p<0,001), lung 
(χ2=13,8318 p<0,001) and blood diseases (χ2=28,1928 
p<0,001), lead to an impairment of patients’ quality of 
life.  
Mucosal symptoms and signs were evaluated in 
Lp and control group: xerostomia, among symptoms, 
and cheilitis, fissured tongue and ulcers, among signs, 
show statistically significant findings. In detail, 30,9% 
of Lp versus 14,5% of controls (χ2 =4,1548 p=0,0415) 
complained xerostomia, with a feeling of mouth 
dryness (sicca syndrome). The main cause appears to 
be a lymphocytic sialadenitis associated with a 
secondary Sjögren’s syndrome. In fact, according to 
Brennan et al., 7,5-30% of Lp have Sjogren syndrome, 
with cheilitis, erythema, hyperkeratotic areas, 
ulcerations, periodontal diseases, atrophic or fissured 
tongue, caries, candidiasis [4,10,29,40,41]. Also drugs 
can cause xerostomia: 74,5% of Lp take corticosteroids 
(p=0,001) from the diagnosis of the disease, often in 
addition to others drugs, such as hydroxychloroquine 
(56,4%), Mycophenolate Mofetil (27,3%), azathioprine 
(14,5%), cyclosporine (10,9%). This remarkable 
symptom is confirmed by the salivary test, with a 
significantly reduced salivary flow in Lp patients. 
Consequently, the hyposalivation may be responsible 
of cheilitis (p=0,0284), fissured tongue (p=0,006) and 
oral ulcers (p=0,045), statistically more frequent in Lp 
than controls.  
A higher prevalence of TMD symptoms was 
detected in Lp (94,5%) compared to the respective 
outcomes in healthy patients (90,9%). However, only 
temple headache (χ2=4,4542 p=0,035) and sensation of 
stuck jaw (Mid-p-test p=0,043) are significant (Table 
5). Myopathies, with reduced muscle strength and 
atrophy, may be part of the disease condition or 
associated with the continuous use of corticosteroid 
therapy. Myofascial pain (MP) evoked by palpation 
was detected in 70,9% Lp and 76,4% of controls 
(χ2=0,4215 p=0,5162), so masticatory muscles show 
overlapping data in both groups (Table 6). The results 
of the present investigation are in accordance with 
literature. To our knowledge, in fact, in no previous 
examined study, pain was elicited during muscles 
palpation, except in Bade's study, who valuated only 
one patient with SLE (masseter, anterior temporal and 
lateral pterygoid muscles were painful) [42].  
Also temporomandibular joint (TMJ) involve-
ment can affect patients with LES, as they have 
changes in the condyles, including flattening, 
erosions, osteophytes and sclerosis. These alterations 
can be linked to disease activity, leading to loss of 
joint cartilage and bone destruction.  
A valuated symptom was arthralgia (pain 
around TMJ area). It is more frequent in Lp (30,9%) 
respect to controls (18,2%), but it isn’t statistically 
significant. This result is in contrast with previous 
studies, where pain during TMJ palpation was always 
found [23,39,42]. 
In this investigation, the presence of TMJ sounds, 
was overall more evident in controls (25,5%) than Lp 




(16,4%), but not significantly different. Also Aliko [23], 
and Jonsson [39] did not found a significant difference 
in Lp and controls. 
Maybe the explanation is that crepitation often 
indicates structural damage to the TMJ and the drugs 
early given in LE could have the potential to reduce or 
slow down joint damage [22]. Moreover, the "healthy" 
sample was selected from people attending at Dental 
Clinic, who could complain TMD more frequently 
than general population, and this could be a limitation 
of the present study.  
The main expected finding was a more severe 
restriction on mandibular movements in Lp patients 
than in controls. Protrusion and left lateral movement 
were significantly different between the two groups. 
In particular, 85,2% of Lp showed limited protrusion 
versus 56,4% of controls (χ2= 10,91 p<0,001); 59,3% of 
Lp had a limitation during left lateral movement 
versus 47,3% of controls (T=2,225 p=0,0282). 
However, the mouth opening value (mean=45,20 
± 8,615) was not statistically significant respect to 
control group (25,5% of Lp versus 23,6% of controls). 
Also Aliko showed a restricted opening only in 4,5% 
of patients [23], while for Jonsonn this sign is 
statistically significant [39]. 
Conclusions  
The aim of this observational study was to 
investigate the prevalence of TMD symptoms and 
signs as well as oral implications in patients with SLE. 
While masticatory muscles have an overlapping 
behavior in both groups, the findings collected show a 
more severe TMJ kinematic impairment in Lp patients 
than in controls, with protrusion and left lateral 
movements significantly different. Also a remarkable 
reduction of salivary flow was detected in Lp 
compared to controls (p<0,0001).  
Lupus, like other autoimmune diseases, seems to 
play a role in oral and TMJ alterations, causing an 
increase in orofacial pain and an impairment of jaw 
mobility. An interdisciplinary collaboration between 
the stomatologist and the rheumatologist would be 
appropriate, thus giving a complete survey of facial 
involvement in course of LES and a more efficient 
treatment of this disease. 
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